Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Ranked by 2024 Global Sales: 1 Ozempic (semaglutide) $16.7 Bn | Novo Nordisk 2 Mounjaro (tirzepatide) $11.5 Bn | Eli Lilly 3 Jardiance (empagliflozin) $9.5 Bn | Boehringer Ingelheim & Eli Lilly 4 Forxiga (dapagliflozin) $7.7 Bn | AstraZeneca 5 Trulicity (dulaglutide) $5.3 Bn | Eli Lilly 6 Rybelsus (semaglutide) $3.2 Bn | Novo Nordisk 7 Humalog (insulin lispro) $2.3 Bn | Eli Lilly 8 NovoRapid (insulin aspart) $2.3 Bn | Novo Nordisk 9 Jentadueto / Trajenta (linagliptin) $1.8 Bn | Boehringer Ingelheim Lantus (insulin glargine) $1.7 Bn | Sanofi Key Insight: The dominance of incretin-based therapies underscores a clear industry shift toward multi-benefit, patient-centric treatments
Lowering your HbA1c by 1% reduces your risk of diabetic kidney, nerve and eye complications by 25%
v3.2.5 The BEST Tracker App For Your GLP Journey
Your response might be faster or slower
This has a direct consequence that researchers frequently miss: results obtained with one suppliers GLOW are not straightforwardly comparable to results obtained with anothers
Descripcin Informacin adicional Rybelsus 14 mg (30 tabletas) (semaglutida), en tabletas de administracin oral, de Novo Nordisk
US$ 29.35
US$ 29.37
US$ 29.12
US$ 28.49
